Filaminast (code name WAY-PDA 641) was a drug candidate developed by Wyeth-Ayerst.
It is a phosphodiesterase 4 inhibitor (
PDE4 inhibitor) and an analog of
rolipram, which served as a prototype molecule for several development efforts.
It was discontinued after a
Phase II trial
The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phase ...
showed that its
therapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.
[
]
See also
* Piclamilast
* Roflumilast
References
{{Drugs for obstructive airway diseases
Abandoned drugs
Carbamates
PDE4 inhibitors
Phenol ethers